Showing results (1-10 of 735) with videos related to
Sort By:
Pageof 74
Trends in Neurosciences|January 5, 2010
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosisOrhan Aktas, Bernd Kieseier, Hans-Peter HartungCurrent Opinion in Neurology|April 2, 2016
Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectivesOrhan Aktas, Philipp Albrecht, Hans-Peter HartungNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 25, 2015
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisJens Ingwersen, Orhan Aktas, Hans-Peter HartungMultiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2014
Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosisHans-Peter Hartung, Orhan Aktas, Alexey N BoykoNature Reviews. Neurology|June 17, 2010
Fingolimod is a potential novel therapy for multiple sclerosisOrhan Aktas, Patrick Küry, Bernd Kieseier, et al.Annals of Neurology|April 27, 2011
The complex world of oligodendroglial differentiation inhibitorsDavid Kremer, Orhan Aktas, Hans-Peter Hartung, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 4, 2019
Monoclonal Antibodies for Multiple Sclerosis: An UpdateJonas Graf, Orhan Aktas, Konrad Rejdak, et al.Current Opinion in Neurology|January 30, 2019
Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspectsMichael Dietrich, Orhan Aktas, Hans-Peter Hartung, et al.Handbook of Clinical Neurology|February 11, 2014
Immune regulation of multiple sclerosisHans-Peter Hartung, Orhan Aktas, Til Menge, et al.Journal of Neurology|November 19, 2009
Development of oral cladribine for the treatment of multiple sclerosisHans-Peter Hartung, Orhan Aktas, Bernd Kieseier, et al.Pageof 74